1-20 of 131
Masatoshi Kudo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Depth of Response Predicts Survival in Unresectable HCC Treated with Immunotherapy: Not All Stable Disease Is Equal

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2025)
https://doi.org/10.1159/000546698
Published Online: 29 May 2025
View articletitled, Depth of Response Predicts Survival in Unresectable HCC Treated with Immunotherapy: Not All Stable Disease Is Equal
Open the PDF for Depth of Response Predicts Survival in Unresectable HCC Treated with Immunotherapy: Not All Stable Disease Is Equal in another window
Journal Articles

Immune Checkpoint Inhibitor plus Anti-VEGF/TKI Combined with Transarterial Chemoembolization in Locally Advanced Nonmetastatic Hepatocellular Carcinoma: Real-World Treatment Strategy Based on Phase 3 Clinical Trial Results

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer 241–247.
https://doi.org/10.1159/000545594
Published Online: 29 March 2025
View articletitled, Immune Checkpoint Inhibitor plus Anti-VEGF/TKI Combined with Transarterial Chemoembolization in Locally Advanced Nonmetastatic Hepatocellular Carcinoma: Real-World Treatment Strategy Based on Phase 3 Clinical Trial Results
Open the PDF for Immune Checkpoint Inhibitor plus Anti-VEGF/TKI Combined with Transarterial Chemoembolization in Locally Advanced Nonmetastatic Hepatocellular Carcinoma: Real-World Treatment Strategy Based on Phase 3 Clinical Trial Results in another window
Journal Articles

Treatment Decision-Making in Unresectable Hepatocellular Carcinoma: Importance of Understanding the Different Response Patterns between IO plus Anti-VEGF and IO plus IO Regimens

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2025) 14 (2): 119–126.
https://doi.org/10.1159/000545163
Published Online: 07 March 2025
View articletitled, Treatment Decision-Making in Unresectable Hepatocellular Carcinoma: Importance of Understanding the Different Response Patterns between IO plus Anti-VEGF and IO plus IO Regimens
Open the PDF for Treatment Decision-Making in Unresectable Hepatocellular Carcinoma: Importance of Understanding the Different Response Patterns between IO plus Anti-VEGF and IO plus IO Regimens in another window
Journal Articles

Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Tatsuya Yamashita, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Kaoru Tsuchiya, Naoya Sakamoto, Shuhei Hige, Ryosuke Take, Kyoko Yamada, Yuki Nakagawa, Hayato Takahashi, Masafumi Ikeda
Journal: Liver Cancer
Liver Cancer (2025)
https://doi.org/10.1159/000544981
Published Online: 03 March 2025
View articletitled, Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150
Open the PDF for Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150 in another window
Journal Articles

Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2025) 14 (1): 1–7.
https://doi.org/10.1159/000543245
Published Online: 20 December 2024
View articletitled, Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
Open the PDF for Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma in another window
Journal Articles

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

Open Access
Subject Area:
Gastroenterology , Oncology
Yoon Jun Kim, Philippe Merle, Richard S. Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Ho Yeong Lim, Masafumi Ikeda, Alessandro Granito, Gianluca Masi, René Gerolami, Sung Bum Cho, Chih-Hung Hsu, Yi-Hsiang Huang, Long-Bin Jeng, Do Young Kim, Shi-Ming Lin, Matthias Pinter, Guoliang Shao, Naoya Kato, Masayuki Kurosaki, Kazushi Numata, Kung-Kai Kuo, Yilei Mao, Yih-Jyh Lin, Kangshun Zhu, Philip Twumasi-Ankrah, Javeed Khan, Maria Awan, Kirhan Ozgurdal, Shukui Qin
Journal: Liver Cancer
Liver Cancer 1–17.
https://doi.org/10.1159/000542285
Published Online: 18 December 2024
View articletitled, Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Open the PDF for Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study in another window
Journal Articles

First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Masafumi Ikeda, Hiroshi Aikata, Kazushi Numata, Hiroyuki Marusawa, Tetsuya Hosaka, Naoya Kato, Masayuki Kurosaki, Manabu Morimoto, Tatsuya Yamashita, Hironori Koga, Tsutomu Masaki, Naoyoshi Yatsuzuka, Masato Suzuki, Satoshi Nagao, Shuichi Kaneko, Hiromitsu Kumada
Journal: Liver Cancer
Liver Cancer 1–13.
https://doi.org/10.1159/000542572
Published Online: 14 November 2024
View articletitled, First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial
Open the PDF for First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial in another window
Journal Articles

Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2024) 13 (6): 573–578.
https://doi.org/10.1159/000542221
Published Online: 24 October 2024
View articletitled, Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence
Open the PDF for Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence in another window
Journal Articles

The Impact of Normal Hepatobiliary Cell Zonation Programs on the Phenotypes and Functions of Primary Liver Tumors

Open Access
Subject Area:
Gastroenterology , Oncology
Tomoko Aoki, Naoshi Nishida, Yasunori Minami, Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2025) 14 (1): 92–103.
https://doi.org/10.1159/000541077
Published Online: 26 August 2024
View articletitled, The Impact of Normal Hepatobiliary Cell Zonation Programs on the Phenotypes and Functions of Primary Liver Tumors
Open the PDF for The Impact of Normal Hepatobiliary Cell Zonation Programs on the Phenotypes and Functions of Primary Liver Tumors in another window
Journal Articles

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2024) 13 (5): 459–467.
https://doi.org/10.1159/000540801
Published Online: 12 August 2024
View articletitled, Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Open the PDF for Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma in another window
Journal Articles

A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization)

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2024) 13 (4): 335–343.
https://doi.org/10.1159/000539301
Published Online: 13 May 2024
View articletitled, A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization)
Open the PDF for A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization) in another window
Journal Articles

Reply to the Letter Regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Kaoru Tsuchiya, Tatsuya Yamashita, Hironori Koga, Yuki Nakagawa, Masafumi Ikeda
Journal: Liver Cancer
Liver Cancer (2024) 13 (6): 671–673.
https://doi.org/10.1159/000539205
Published Online: 06 May 2024
View articletitled, Reply to the Letter Regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”
Open the PDF for Reply to the Letter Regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study” in another window
Journal Articles

Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2024) 13 (3): 227–234.
https://doi.org/10.1159/000538558
Published Online: 17 April 2024
View articletitled, Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
Open the PDF for Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma in another window
Journal Articles

Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study

Open Access
Subject Area:
Gastroenterology , Oncology
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Silvia Foti, Silvia Camera, Bernardo Stefanini, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, Margherita Rimini
Journal: Liver Cancer
Liver Cancer (2024) 13 (5): 522–536.
https://doi.org/10.1159/000537915
Published Online: 10 April 2024
View articletitled, Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
Open the PDF for Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study in another window
Journal Articles

Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT

Open Access
Subject Area:
Gastroenterology , Oncology
Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R. Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2024) 13 (5): 537–547.
https://doi.org/10.1159/000537947
Published Online: 26 February 2024
View articletitled, Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT
Open the PDF for Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT in another window
Journal Articles

Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study

Open Access
Subject Area:
Gastroenterology , Oncology
Richard S. Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Ramil Abdrashitov, Yaxi Chen, Songzi Li, Andrew X. Zhu, Shukui Qin, Arndt Vogel
Journal: Liver Cancer
Liver Cancer (2024) 13 (5): 548–560.
https://doi.org/10.1159/000537966
Published Online: 21 February 2024
View articletitled, Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study
Open the PDF for Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study in another window
Journal Articles

Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2024) 13 (2): 113–118.
https://doi.org/10.1159/000537897
Published Online: 20 February 2024
View articletitled, Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma
Open the PDF for Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma in another window
Journal Articles

Objective Response to Systemic Therapy Is a Strong Predictor of Overall Survival in Patients with Unresectable Hepatocellular Carcinoma

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2024) 13 (1): 1–5.
https://doi.org/10.1159/000535516
Published Online: 29 November 2023
View articletitled, Objective Response to Systemic Therapy Is a Strong Predictor of Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
Open the PDF for Objective Response to Systemic Therapy Is a Strong Predictor of Overall Survival in Patients with Unresectable Hepatocellular Carcinoma in another window
Journal Articles

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, Ryosuke Take, Kyoko Yamada, Takashi Asakawa, Yuki Nakagawa, Masafumi Ikeda
Journal: Liver Cancer
Liver Cancer (2024) 13 (4): 401–412.
https://doi.org/10.1159/000535501
Published Online: 28 November 2023
View articletitled, Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Open the PDF for Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study in another window
Journal Articles

A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116

Open Access
Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari D. Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Zahra Ramji, Leonid Dubrovsky, Josep M. Llovet
Journal: Liver Cancer
Liver Cancer (2024) 13 (4): 451–457.
https://doi.org/10.1159/000535154
Published Online: 13 November 2023
View articletitled, A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Open the PDF for A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116 in another window